# Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma

Source: https://onco.cc/key-papers/paper-onken-uveal-melanoma-gene-expression-coog-ophthalmology-2012/  
OnCo record `paper-onken-uveal-melanoma-gene-expression-coog-ophthalmology-2012` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A prospective study in 459 people with eye melanoma confirming that a gene-activity test separates a low-risk class from a high-risk class for spread.

## Summary

Metastasis was detected in 3 class 1 cases (1.1 per cent) and 44 class 2 cases (25.9 per cent).

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Ophthalmology
- Year: 2012
- DOI: 10.1016/j.ophtha.2012.02.017
- Authors: Onken MD, Worley LA, Char DH, et al.
- Findings: Metastasis in 1.1% of class 1 and 25.9% of class 2 cases.
- What it means: The class guides how closely the liver is watched after treatment of the eye.
- Caveats: Follow-up shorter than the time over which many metastases appear.

## Sources

- Onken et al., Ophthalmology 2012: https://doi.org/10.1016/j.ophtha.2012.02.017
- PubMed: https://pubmed.ncbi.nlm.nih.gov/22521086/

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/)
- drugs: [DecisionDx-UM](https://onco.cc/drugs/decisiondx-um/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-onken-uveal-melanoma-gene-expression-coog-ophthalmology-2012.json